Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

43
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
43
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

222
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
222
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

12.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.4K
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

86
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
86
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters00:54

Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters

58
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
58
Quantifying and Rejecting Outliers: The Grubbs Test01:02

Quantifying and Rejecting Outliers: The Grubbs Test

1.5K
Sometimes, a data set can have a recorded numerical observation that greatly  deviates from the rest of the data. Assuming that the data is normally distributed, a statistical method called the Grubbs test can be used to determine whether the observation is truly an outlier.  To perform a two-tailed Grubbs test, first, calculate the absolute difference between the outlier and the mean. Then, calculate the ratio between this difference and the standard deviation of the sample. This...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficient semi-supervised estimation of optimal individualized treatment regimes with survival outcome.

Statistical methods in medical research·2026
Same author

An ensemble approach to tensor learning.

Statistical methods in medical research·2026
Same author

Diagnostic accuracy for multiple categories: statistical advice.

The British journal of psychiatry : the journal of mental science·2025
Same author

A Varying-Coefficient Additive Hazard Model for Recurrent Events Data.

Statistics in medicine·2025
Same author

Efficient Risk Assessment of Time-to-Event Targets With Adaptive Information Transfer.

Statistics in medicine·2024
Same author

Transformed ROC Curve for Biomarker Evaluation.

Statistics in medicine·2024

Related Experiment Video

Updated: Jun 2, 2025

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER
14:06

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER

Published on: June 23, 2012

15.2K

Change surface regression for nonlinear subgroup identification with application to warfarin pharmacogenomics data.

Pan Liu1, Yaguang Li2, Jialiang Li1

  • 1Department of Statistics and Data Science, National University of Singapore, Singapore 117546, Singapore.

Biometrics
|January 16, 2025
PubMed
Summary

This study introduces a new change surface model to identify patient subgroups for personalized medicine. The model reveals complex drug-gene interactions, improving understanding of warfarin dosing variability.

Keywords:
change surfacepersonalized medicinepharmacogenomicssubgroup identificationtreatment recommendationwarfarin dosing

More Related Videos

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

3.5K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

15.6K

Related Experiment Videos

Last Updated: Jun 2, 2025

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER
14:06

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER

Published on: June 23, 2012

15.2K
Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

3.5K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

15.6K

Area of Science:

  • Genetics and Genomics
  • Pharmacology
  • Biostatistics

Background:

  • Pharmacogenomics is key to personalized medicine, optimizing drug efficacy and reducing adverse effects by studying genetic variations.
  • Drug metabolism complexity and nongenetic factors create heterogeneity in drug response across populations.
  • Existing methods struggle with complex, high-dimensional datasets like the International Warfarin Pharmacogenetic Consortium (IWPC) data.

Purpose of the Study:

  • To develop a novel change surface model for identifying patient subgroups with distinct drug-gene associations.
  • To capture and model between-patient heterogeneity in drug dosing requirements.
  • To provide a clearer understanding of dynamic drug-gene associations in complex datasets.

Main Methods:

  • Formulation of a novel change surface model for multiple subgroup identification.
  • Accommodation of nonlinear subgroup divisions and handling of high-dimensional data via a doubly penalized approach.
  • An iterative 2-stage method combining change point detection and smoothed local adaptive majorize-minimization for surface regression.

Main Results:

  • The proposed model effectively identifies nonlinear subgroup structures in complex data.
  • Extensive numerical studies demonstrate the method's performance.
  • Application to the IWPC dataset identified 3 distinct patient subgroups with unique pharmacogenomic relationships.

Conclusions:

  • The change surface model offers a powerful approach for subgroup identification in pharmacogenomics.
  • This method enhances understanding of drug-gene associations and patient heterogeneity.
  • Findings contribute valuable insights for personalized medicine, particularly in warfarin dosing.